BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19863361)

  • 1. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.
    Anzueto A; Ferguson GT; Feldman G; Chinsky K; Seibert A; Emmett A; Knobil K; O'Dell D; Kalberg C; Crater G
    COPD; 2009 Oct; 6(5):320-9. PubMed ID: 19863361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone.
    Bailey W; Castro M; Matz J; White M; Dransfield M; Yancey S; Ortega H
    Curr Med Res Opin; 2008 Jun; 24(6):1669-82. PubMed ID: 18462564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
    Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.
    Hanania NA; Darken P; Horstman D; Reisner C; Lee B; Davis S; Shah T
    Chest; 2003 Sep; 124(3):834-43. PubMed ID: 12970006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.
    Ohar JA; Crater GD; Emmett A; Ferro TJ; Morris AN; Raphiou I; Sriram PS; Dransfield MT
    Respir Res; 2014 Sep; 15(1):105. PubMed ID: 25248764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
    Wedzicha JA; Calverley PM; Seemungal TA; Hagan G; Ansari Z; Stockley RA;
    Am J Respir Crit Care Med; 2008 Jan; 177(1):19-26. PubMed ID: 17916806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
    Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.
    Dalal AA; St Charles M; Petersen HV; Roberts MH; Blanchette CM; Manavi-Zieverink K
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():179-87. PubMed ID: 20714371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
    Delea TE; Hagiwara M; Dalal AA; Stanford RH; Blanchette CM
    Curr Med Res Opin; 2009 Jan; 25(1):1-13. PubMed ID: 19210134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
    Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
    Magnussen H; Disse B; Rodriguez-Roisin R; Kirsten A; Watz H; Tetzlaff K; Towse L; Finnigan H; Dahl R; Decramer M; Chanez P; Wouters EF; Calverley PM;
    N Engl J Med; 2014 Oct; 371(14):1285-94. PubMed ID: 25196117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
    Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
    Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.